Most Popular
-
6
Chaos unfolds as rare November snowstorm grips Korea for 2nd day
-
7
BOK makes surprise 2nd rate cut to boost growth
-
8
‘VCHA, Katseye and Dear Alice are not K-pop groups,’ industry experts say
-
9
[Graphic News] South Koreans favor Japan for repeat overseas trips
![[Graphic News] South Koreans favor Japan for repeat overseas trips](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/27/20241127050101_0.gif&u=)
-
10
Ador claims exclusive contracts with NewJeans still valid
![[Graphic News] South Koreans favor Japan for repeat overseas trips](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/27/20241127050101_0.gif&u=)
Samsung Bioepis to spend 180.4 bln won on new R&D center
By YonhapPublished : March 7, 2019 - 20:04
South Korean biopharmaceutical firm Samsung Bioepis Co. will spend 180.4 billion won ($159.7 million) to build a new research and development center, its parent company said Thursday.
The investment cost accounts for 36.44 percent of the company's capital at the end of 2017, Samsung BioLogics, a biopharmaceutical unit of South Korea's top conglomerate Samsung Group, said in a regulatory filing.
"The construction of the R&D facility is intended to strengthen competitiveness," the company said.
The investment cost accounts for 36.44 percent of the company's capital at the end of 2017, Samsung BioLogics, a biopharmaceutical unit of South Korea's top conglomerate Samsung Group, said in a regulatory filing.
"The construction of the R&D facility is intended to strengthen competitiveness," the company said.
Samsung Bioepis, which was established in 2012 in a joint venture between Samsung Biologics and Biogen Inc., mostly manufactures biosimilars.
The market for biosimilars has grown in recent years as such drugs are available to customers at a discount. Biosimilars are officially approved copycat medicines developed after patents for the original biopharmaceuticals expire. (Yonhap)
